

Cancer de la Prostate (Etude ProGene) / Prostate Cancer	200
Cancer de la Vessie et des Voies Excrétrices Supérieures / Bladder & Upper Urinary Tract Cancer	75
Cancer du Rein / Kidney Cancer	14

Cancer de la Prostate (Etude ProGene) / Prostate Cancer

1. Audouin M, Girshovich A, Cussenot O, Renard-Penna R. Typology of intravesical prostatic protrusions, or so-called median lobes, in middle-aged and older men. *Surg Radiol Anat.* 2018 Mar 13 (sous presse).
2. Tavolaro S, Mozer P, Roupret M, Comperat E, Rozet F, Barret E, Drouin S, Vaessen C, Lucidarme O, Cussenot O, Boudghène F, Renard-Penna R. Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. *Diagn Interv Imaging.* 2018 Feb 21. pii: S2211-5684(18)30008-1.
3. Lebdaï S, Lunelli L, Bigot P, Cussenot O, Azzouzi AR. Focal therapies: An alternative option for low-risk prostate cancer management?. *Presse Med.* 2017 Oct;46(10):935-939.
4. Renard-Penna R, Mozer P, Lunelli L, Cussenot O. Role of prostate MRI, TRUS fusion biopsies and new markers in the diagnostic strategy of prostate cancer. *Presse Med.* 2017 Oct;46(10):928-934.
5. Cussenot O. Management of prostate cancer: The new challenges. *Presse Med.* 2017 Oct;46(10):923-927.
6. Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *J Natl Cancer Inst.* 2017 Aug 1;109(8).
7. Larson NB, McDonnell S, Cannon Albright L, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson JE, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. *Genet Epidemiol.* 2017 May;41(4):297-308. Erratum in: *Genet Epidemiol.* 2017 Nov;41(7):710.
8. Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottureau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN. PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of (68)Ga-PSMA-11 when (18)F-fluorocholine is non-contributive. *Prog Urol.* 2017 Jun- Jul;27(8-9):474-481.
9. Marin L, Ezziane M, Comperat E, Mozer P, Cancel-Tassin G, Coté JF, Racoceanu D, Boudghene F, Lucidarme O, Cussenot O, Renard Penna R. Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. *Diagn Interv Imaging.* 2017 May;98(5):423-428.
10. Léon P, Cancel-Tassin G, Koutlidis N, Calves J, Funes de la Vega M, Fournier G, Valeri A, Cormier L, Larré S, Cussenot O. Prevalence and diversity of management of prostate

- cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study. *Prog Urol.* 2017 Mar;27(3):158-165.
11. Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Lévesque E, Cancel-Tassin G. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. *World J Urol.* 2017 Feb;35(2):293-298.
 12. Rozet F, Hennequin C, Beauval JB, Beuzebec P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Lebre T, Rebillard X, Soulié M, Renard-Penna R, Méjean A. CCAFU french national guidelines 2016-2018 on prostate cancer. *Prog Urol.* 2016 Nov;27 Suppl 1:S95-S143.
 13. Munbahuhal G, Seisen T, Gomez FD, Peyronnet B, Cussenot O, Shariat SF, Roupret M. Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. *Cancer Treat Rev.* 2016 Nov;50:228-239.
 14. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MaInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet.* 2016 Oct 6;99(4):877-885.
 15. Larson NB, McDonnell S, Albright LC, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson J, Cussenot O, Cancel-Tassin G, Giles G, MaInnis R, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genet Epidemiol.* 2016 Sep;40(6):461-9. Erratum in: *Genet Epidemiol.* 2017 Nov;41(7):710.
 16. Renard Penna R, Cancel-Tassin G, Comperat E, Mozer P, Léon P, Varinot J, Roupret M, Bitker MO, Lucidarme O, Cussenot O. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. *World J Urol.* 2016 Oct;34(10):1389-95.
 17. Teerlink CC, Leongamornlert D, Dadaev T, Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid DJ, Catalona WJ, Zheng SL, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Giles GG, Southey MC, Fitzgerald LM, Rinckleb A, Luedeke M, Maier C, Stanford JL, Ostrander EA, Kaikkonen EM, Sipeky C, Tammela T, Schleutker J, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cancel-Tassin G, Cussenot O, Mandal D, Laurie C, Laurie C; PRACTICAL consortium; International Consortium for Prostate Cancer Genetics, Thibodeau SN, Eeles RA, Kote-Jarai Z, Cannon-Albright L. Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. *Hum Genet.* 2016 Aug;135(8):923-38.
 18. Seisen T, Roupret M, Gomez F, Malouf GG, Shariat SF, Peyronnet B, Spano JP, Cancel-Tassin G, Cussenot O. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treat Rev.* 2016 Jul;48:25-33.
 19. Cornu JN, Cancel-Tassin G, Cox DG, Roupret M, Koutlidis N, Bigot P, Valeri A, Ondet V, Gaffory C, Fournier G, Azzouzi AR, Cormier L, Cussenot O. Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population. *Eur Urol.* 2016 Jul;70(1):6-8.
 20. Renard-Penna R, Roupret M, Compérat E, Rozet F, Granger B, Barkatz J, Bitker MO, Lucidarme O, Cussenot O, Mozer P. Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. *World J Urol.* 2016 May;34(5):673-8.
 21. Varinot J, Furudoï A, Drouin S, Phe V, Penna RR, Roupret M, Bitker MO, Cussenot O, Compérat E. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. *Virchows Arch.* 2016 May;468(5):619-22.
 22. Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, Georges A, Larré S, Loric S, Luporsi E, Martin PM, Mazerolles C, Molinié V, Mongiat-Artus P, Piffret J, Thuillier

- F, Perrin P, Rebillard X; Groupe de biologie de la prostate. The level of evidence for the use of biomarkers in the early detection of prostate cancer. *Ann Biol Clin (Paris)*. 2016 Mar-Apr;74(2):227-32.
23. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorransoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Krickler A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-García A, Pavanello S, Peeters PH, Peng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupert M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst*. 2015 Oct 12;107(12):djv279. Erratum in: *J Natl Cancer Inst*. 2016 Apr;108(4). pii: djw106.

24. Audouin M, Benbouzid S, Terrasa JB, Proietti S, Cussenot O, Lukacs B, Cornu JN. Evaluation of postoperative symptoms after Greenlight™ photovaporization of the prostate through a dedicated questionnaire. *Prog Urol*. 2016 Feb;26(2):108-14.
25. Roumiguié M, Beauval JB, Bordier B, Filleron T, Rozet F, Ruffion A, Mottet N, Cussenot O, Malavaud B. What risk of prostate cancer led urologist to recommend prostate biopsies? *Prog Urol*. 2015 Dec;25(16):1125-31.
26. Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Léon P, Roupret M, Mozer P, Vaessen C, Lucidarme O, Bitker MO, Cussenot O. Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. *J Urol*. 2015 Dec;194(6):1617-23.
27. Cussenot O, Cancel-Tassin G. Precision medicine in oncology needs to integrate pharmacogenetic profiling. *Eur Urol*. 2015 Oct;68(4):630-1.
28. de Gorski A, Rouprêt M, Peyronnet B, Le Cossec C, Granger B, Comperat E, Cussenot O, Renard-Penna R, Mozer P. Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. *J Urol*. 2015 Sep;194(3):669-73.
29. Léon P, Seisen T, Cussenot O, Drouin SJ, Cattarino S, Compérat E, Renard-Penna R, Mozer P, Bitker MO, Rouprêt M. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. *Urol Oncol*. 2015 Sep;33(9):384.e21-7.
30. Renard-Penna R, Cancel-Tassin G, Comperat E, Roupret M, Mozer P, Cussenot O. Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. *World J Urol*. 2015 Jul;33(7):929-36.
31. van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. *World J Urol*. 2015 Jul;33(7):907-16.
32. Kozal S, Peyronnet B, Cattarino S, Seisen T, Comperat E, Vaessen C, Mozer P, Renard-Penna R, Cussenot O, Rouprêt M, Drouin SJ. Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study. *Urol Oncol*. 2015 Jul;33(7):330.e1-7.
33. Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Grönberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindström S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkum F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H; African Ancestry Prostate Cancer GWAS Consortium, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ. Two susceptibility loci identified for prostate cancer aggressiveness. *Nat Commun*. 2015 May 5;6:6889.
34. Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. *Hum Genet*. 2015 Apr;134(4):439-50.
35. Cattarino S, Seisen T, Drouin SJ, Renard-Penna R, Léon P, Comperat E, Mozer P, Cussenot O, Rouprêt M. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. *Can J Urol*. 2015 Apr;22(2):7703-8.
36. Hurel S, Rouprêt M, Seisen T, Comperat E, Phé V, Droupy S, Audenet F, Pignot G, Cathelineau X, Guy L, Cussenot O, Ouzzane A, Bozzini G, Nison L, Ruffion A, Colin P. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. *World J Urol*. 2015 Mar;33(3):335-41.
37. Talbot JN, Gligorov J, Nataf V, Montravers F, Huchet V, Michaud L, Ohnona J, Balogova S, Cussenot O, Daraï E, Lotz JP, Kerrou K. Current applications of PET imaging of sex

- hormone receptors with a fluorinated analogue of estradiol or of testosterone. *Q J Nucl Med Mol Imaging*. 2015 Mar;59(1):4-17.
38. Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L. Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). *Asian J Androl*. 2015 Jan-Feb;17(1):117-9.
 39. Mozer P, Rouprêt M, Le Cossec C, Granger B, Comperat E, de Gorski A, Cussenot O, Renard-Penna R. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. *BJU Int*. 2015 Jan;115(1):50-7.
 40. Cussenot O, Cancel-Tassin G. Update on genetic predisposition to prostate cancer. *Bull Cancer*. 2015 Jan;102(1):53-6.
 41. Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, Renard-Penna R, Mozer P, Guechot J, Cussenot O. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. *Prostate*. 2015 Jan;75(1):103-11.
 42. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G Jr, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF Jr, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R 3rd, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD 3rd, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kaminen A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierrri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL,

- Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Hum Mol Genet.* 2014 Dec 15;23(24):6616-33.
43. Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G. Expression patterns of candidate susceptibility genes HNF1 β and CtBP2 in prostate cancer: association with tumor progression. *Urol Oncol.* 2014 May;32(4):426-32.
 44. Cussenot O, Cornu JN, Drouin SJ, Mozer P, Egrot C, Vaessen C, Haab F, Bitker MO, Rouprêt M. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. *World J Urol.* 2014 Apr;32(2):545-50.
 45. Drouin SJ, Comperat E, Varinot J, Vaessen C, Bitker MO, Chartier-Kastler E, Mozer P, Shariat SF, Cussenot O, Rouprêt M. The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. *World J Urol.* 2014 Apr;32(2):489-93.
 46. Dariane C, Le Cossec C, Drouin SJ, Wolff B, Granger B, Mozer P, Bitker MO, Shariat SF, Cussenot O, Rouprêt M. Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. *World J Urol.* 2014 Apr;32(2):481-7.
 47. Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Grönberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J; International Consortium for Prostate Cancer Genetics, Camp NJ, Cannon-Albright LA. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. *Hum Genet.* 2014 Mar;133(3):347-56.
 48. Varinot J, Cussenot O, Roupret M, Conort P, Bitker MO, Chartier-Kastler E, Cheng L, Compérat E. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. *Virchows Arch.* 2013 Dec;463(6):803-9.
 49. Lukacs B, Cornu JN, Aout M, Tessier N, Hodée C, Haab F, Cussenot O, Merlière Y, Moysan V, Vicaut E. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. *Eur Urol.* 2013 Sep;64(3):493-501.
 50. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, Cathelineau X, Cussenot O. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. *Hum Pathol.* 2013 Aug;44(8):1617-23.
 51. Lasselín J, Drouin SJ, Champy CM, Léon P, Casenave J, Cussenot O, Bitker MO, Rouprêt M. Influence of plasmatic testosterone during natural history of prostate cancer: a review. *Prog Urol.* 2013 Jun;23(7):438-43.
 52. Eisinger F, Cancel-Tassin G, Azzouzi AR, Gravis G, Rossi D, Cussenot O. Pharmacologic and diet based prostate cancer prevention. *Bull Cancer.* 2013 May;100(5):497-507.
 53. Bigot P, Mouzat K, Lebdaï S, Bahut M, Benhabiles N, Tassin GC, Azzouzi AR, Cussenot O. Quantitative proteomic determination of diethylstilbestrol action on prostate cancer. *Asian J Androl.* 2013 May;15(3):413-20.
 54. Terrasa JB, Cornu JN, Haab F, Cussenot O, Lukacs B. Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate. *J Sex Med.* 2013 May;10(5):1363-71.
 55. Seisen T, Drouin SJ, Phé V, Parra J, Mozer P, Bitker MO, Cussenot O, Rouprêt M. Current role of image-guided robotic radiosurgery (Cyberknife®) for prostate cancer treatment. *BJU Int.* 2013 May;111(5):761-6.
 56. Cussenot O, Rozet F, Ruffion A, Mottet N, Bordier B, Malavaud B, Meesen B, Stoevelaar H. The management of prostate cancer: a retrospective chart review in 808 French men undergoing biopsy. *Prog Urol.* 2013 Apr;23(5):347-55.

57. Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, Montravers F, Cussenot O, Talbot JN. Effect of erythropoietin on bone marrow uptake of ¹⁸F-fluorocholine in prostate cancer: comparison with ¹⁸F-fluoride uptake. *Clin Nucl Med*. 2013 Mar;38(3):200-2.
58. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. *Prostate*. 2013 Feb 15;73(3):242-9.
59. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, DeRycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Grönberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB; International Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet*. 2013 Jan;132(1):5-14.
60. Malavaud B, Cussenot O, Mottet N, Rozet F, Ruffion A, Smets L, Stoevelaar H. Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France. *J Med Econ*. 2013;16(3):358-63.
61. Abdou A, Cornu JN, Sèbe P, Ciofu C, Peyrat L, Cussenot O, Haab F. Salvage therapy with artificial urinary sphincter after Advance™ male sling failure for post-prostatectomy incontinence: a first clinical experience. *Prog Urol*. 2012 Oct;22(11):650-6.
62. Cornu JN, Terrasa JB, Cussenot O, Haab F, Lukacs B. Evolution of the landscape of surgical management of prostate cancer in France: the case of radical prostatectomy. *Eur Urol*. 2012 Oct;62(4):735-6.
63. Cornu JN, Lizée D, Sèbe P, Peyrat L, Ciofu C, Cussenot O, Haab F. TVT SECUR single-incision sling after 5 years of follow-up: the promises made and the promises broken. *Eur Urol*. 2012 Oct;62(4):737-8.
64. Yates DR, Rouprêt M, Drouin SJ, Comperat E, Ricci S, Lacave R, Sèbe P, Cancel-Tassin G, Bitker MO, Cussenot O. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. *Prostate*. 2012 Sep 1;72(12):1382-8.
65. Fromont G, Rozet F, Cathelineau X, Ouzzane A, Doucet L, Fournier G, Cussenot O. BCAR1 expression improves prediction of biochemical recurrence after radical prostatectomy. *Prostate*. 2012 Sep 1;72(12):1359-65.
66. Drouin SJ, Comperat E, Cussenot O, Bitker MO, Haertig A, Rouprêt M. Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. *Urol Oncol*. 2012 Jul-Aug;30(4):402-7.
67. Wang Z, Parikh H, Jia J, Myers T, Yeager M, Jacobs KB, Hutchinson A, Burdett L, Ghosh A, Thun MJ, Gapstur SM, Ryan Diver W, Virtamo J, Albanes D, Cancel-Tassin G, Valeri A, Cussenot O, Offit K, Giovannucci E, Ma J, Stampfer MJ, Michael Gaziano J, Hunter DJ, Dutra-Clarke A, Kirchhoff T, Alavanja M, Freeman LB, Koutros S, Hoover R, Berndt SI, Hayes RB, Agalliu I, Burk RD, Wacholder S, Thomas G, Amundadottir L. Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry. *Hum Genet*. 2012 Jul;131(7):1173-85.
68. Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Grönberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J; International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet*. 2012 Jul;131(7):1095-103.
69. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch

- MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebring S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Bochum S, Hoegel J, Grönberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB; International Consortium for Prostate Cancer Genetics. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. *BMC Med Genet*. 2012 Jun 19;13:46.
70. Larré S, Camparo P, Comperat E, Boulbés D, Haddoum M, Baulande S, Soularue P, Costa P, Cussenot O. Biological effect of human serum collected before and after oral intake of *Pygeum africanum* on various benign prostate cell cultures. *Asian J Androl*. 2012 May;14(3):499-504.
 71. Audenet F, Seringe E, Drouin SJ, Comperat E, Cussenot O, Bitker MO, Rouprêt M. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. *World J Urol*. 2012 Apr;30(2):239-44.
 72. Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, FitzGerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. *Prostate*. 2012 Mar;72(4):410-26.
 73. Seisen T, Rouprêt M, Azzouzi AR, Cussenot O, Rozet F. Active surveillance for the secondary prevention of prostate cancer. *Prog Urol*. 2012 Feb;22(2 Suppl 1):H10-4.
 74. Giton F, Fiet J, Cornu JN, Cussenot O, Bélanger A, Urien S, Oliva A, Blanchet P, Multigner L. Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry. *Eur J Endocrinol*. 2011 Dec;165(6):917-24.
 75. Audenet F, Comperat E, Seringe E, Drouin SJ, Richard F, Cussenot O, Bitker MO, Rouprêt M. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score \geq 8: a single-center experience. *Urol Oncol*. 2011 Nov-Dec;29(6):602-7.
 76. Cornu JN, Doucet C, Sèbe P, Ciofu C, Gil Diez de Medina S, Vallancien G, Amarenco G, Cussenot O, Pinset C, Haab F. Prospective evaluation of intrasphincteric injections of autologous muscular cells in patients with stress urinary incontinence following radical prostatectomy. *Prog Urol*. 2011 Nov;21(12):859-65.
 77. Ciampa J, Yeager M, Jacobs K, Thun MJ, Gapstur S, Albanes D, Virtamo J, Weinstein SJ, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Hunter D, Hoover R, Thomas G, Chanock S, Holmes C, Chatterjee N. Application of a novel score test for genetic association incorporating gene-gene interaction suggests functionality for prostate cancer susceptibility regions. *Hum Hered*. 2011;72(3):182-93.
 78. Masson-Lecomte A, Hupertan V, Comperat E, Vaessen C, Chartier-Kastler E, Cussenot O, Bitker MO, Rouprêt M. Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. *World J Urol*. 2011 Oct;29(5):665-70.
 79. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. *Q J Nucl Med Mol Imaging*. 2011 Aug;55(4):448-57.
 80. Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njølstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chanock SJ. Large-scale

- fine mapping of the HNF1B locus and prostate cancer risk. *Hum Mol Genet.* 2011 Aug 15;20(16):3322-9.
81. Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SI, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njølstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. *Hum Mol Genet.* 2011 Jul 15;20(14):2869-78.
 82. Cornu JN, Sèbe P, Ciofu C, Peyrat L, Cussenot O, Haab F. Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. *BJU Int.* 2011 Jul;108(2):236-40.
 83. Parikh H, Wang Z, Pettigrew KA, Jia J, Daugherty S, Yeager M, Jacobs KB, Hutchinson A, Burdett L, Cullen M, Qi L, Boland J, Collins I, Albert TJ, Vatten LJ, Hveem K, Njølstad I, Cancel-Tassin G, Cussenot O, Valeri A, Virtamo J, Thun MJ, Feigelson HS, Diver WR, Chatterjee N, Thomas G, Albanes D, Chanock SJ, Hunter DJ, Hoover R, Hayes RB, Berndt SI, Sampson J, Amundadottir L. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. *Hum Genet.* 2011 Jun;129(6):675-85.
 84. Cornu JN, Drouin S, Cancel-Tassin G, Bigot P, Azzouzi AR, Koutlidis N, Cormier L, Gaffory C, Rouprêt M, Sèbe P, Bitker MO, Haab F, Cussenot O. Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study. *Mol Med.* 2011 May-Jun;17(5-6):473-7. Ciampa J, Yeager M, Amundadottir L, Jacobs K, Kraft P, Chung C, Wacholder S, Yu K, Wheeler W, Thun MJ, Diver WR, Gapstur S, Albanes D, Virtamo J, Weinstein S, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Hunter D, Hoover R, Thomas G, Chanock S, Chatterjee N. Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. *Cancer Res.* 2011 May 1;71(9):3287-95.
 85. Cussenot O, Comperat E, Bitker MO, Rouprêt M. From active surveillance to the concept of secondary prevention. *Eur Urol.* 2011 Apr;59(4):568-71.
 86. Fromont G, Cussenot O. The integrin signalling adaptor p130CAS is also a key player in prostate cancer. *Nat Rev Cancer.* 2011 Mar;11(3):227.
 87. Fromont G, Validire P, Prapotnich D, Rozet F, Vallancien G, Cussenot O, Cathelineau X. Pathologic reassessment of prostate cancer surgical specimens before molecular retrospective studies. *Clin Cancer Res.* 2011 Feb 15;17(4):836-40.
 88. Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O. Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. *Eur Urol.* 2011 Feb;59(2):197-201.
 89. Bitker MO, Roupret M, Cussenot O. Toward a new border. *Prog Urol.* 2011 Feb;21(2):154-5.
 90. Cornu JN, Merlet B, Ciofu C, Mouly S, Peyrat L, Sèbe P, Yiou R, Vallancien G, Debrix I, Laribi K, Cussenot O, Haab F. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. *Eur Urol.* 2011 Jan;59(1):148-54.
 91. Haab F, Beley S, Cornu JN, Culine S, Cussenot O, Hennequin C. Urinary and sexual disorders following localised prostate cancer management. *Bull Cancer.* 2010 Dec;97(12):1537-49.
 92. Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C. High-risk clinically localised prostate cancer. *Bull Cancer.* 2010 Dec;97(12):1517-36.
 93. Valeri A, Malavaud B, Desrichard O, Cornu JN, Blanchet P, Dervaux B, Puech P, Villers A, Cancel-Tassin G, Cussenot O. Strategies for early diagnosis and prevention of prostate cancer. *Bull Cancer.* 2010 Dec;97(12):1499-515.
 94. Cussenot O. The Campaign Program for Prostate Integrated Research. *Bull Cancer.* 2010 Dec;97(12):1497-8.
 95. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. *J Urol.* 2010 Nov;184(5):2172-8.

96. Comp erat E, Roupr et M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A, Cancel-Tassin G, Cussenot O. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. *Prostate*. 2010 Nov 1;70(15):1622-7.
97. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. *Eur Urol*. 2010 Sep;58(3):450-6.
98. Cornu JN, S ebe P, Peyrat L, Ciofu C, Cussenot O, Haab F. Midterm prospective evaluation of TVT-Secur reveals high failure rate. *Eur Urol*. 2010 Jul;58(1):157-61.
99. Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Spencer Feigelson H, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Gr nberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. *Cancer Epidemiol Biomarkers Prev*. 2010 May;19(5):1349-55.
100. Ph e V, Cussenot O, Roupr et M. Methylated genes as potential biomarkers in prostate cancer. *BJU Int*. 2010 May;105(10):1364-70.
101. Cussenot O. Developing strategies for active surveillance. *Rev Infirm*. 2010 Mar;(158):25-6.
102. Comp erat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F. Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. *Anal Quant Cytol Histol*. 2010 Feb;32(1):39-44.
103. Cornu JN, S ebe P, Ciofu C, Peyrat L, Beley S, Tligui M, Lukacs B, Traxer O, Cussenot O, Haab F. The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. *Eur Urol*. 2009 Dec;56(6):923-7.
104. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G. Differential expression of the semaphorin 3A pathway in prostatic cancer. *Histopathology*. 2009 Oct;55(4):392-8.
105. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, Kraft P, Wacholder S, Orr N, Berndt S, Yu K, Hutchinson A, Wang Z, Amundadottir L, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Kumle M, Tucker M, Gerhard DS, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chanock SJ. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. *Nat Genet*. 2009 Oct;41(10):1055-7.
106. Nguyen K, Eltz S, Drouin SJ, Comperat E, Audenet F, Renard-Penna R, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Roupr et M. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. *World J Urol*. 2009 Oct;27(5):653-8.
107. Roupr et M, Hupertan V, Comperat E, Drouin SJ, Ph e V, Xylinas E, Demanse D, Sibony M, Richard F, Cussenot O. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. *BJU Int*. 2009 Sep;104(6):813-7; discussion 817-8.
108. Xylinas E, Misra  V, Comperat E, Renard-Penna R, Vaessen C, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Roupr et M. Oncologic and functional outcomes after radical prostatectomy in T3 prostate cancer. *Prog Urol*. 2009 May;19(5):285-90.
109. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF Jr, Thomas G, Hunter DJ, Dean M, Chanock SJ. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. *Proc Natl Acad Sci U S A*. 2009 May 12;106(19):7933-8.

110. Xylinas E, Drouin SJ, Comperat E, Vaessen C, Renard-Penna R, Misrai V, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Roupret M. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. *BJU Int*. 2009 May;103(9):1173-8; discussion 1178.
111. Henry N, Sebe P, Cussenot O. Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. *Nat Clin Pract Urol*. 2009 Mar;6(3):164-7.
112. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, Fournier G, Giordanella JP, Pouchard M, Escary JL, Valeri A, Cussenot O. Association between estrogen and androgen receptor genes and prostate cancer risk. *Eur J Endocrinol*. 2009 Jan;160(1):101-6.
113. Cussenot O, Azzouzi AR, Bantsimba-Malanda G, Gaffory C, Mangin P, Cormier L, Fournier G, Valeri A, Jouffe L, Roupret M, Fromont G, Sibony M, Comperat E, Cancel-Tassin G. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. *Clin Cancer Res*. 2008 Sep 1;14(17):5635-9.
114. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O, Thomas G, Hunter DJ, Fraumeni JF Jr, Hoover RN, Chanock SJ, Hayes RB. Variation in *KLK* genes, prostate-specific antigen and risk of prostate cancer. *Nat Genet*. 2008 Sep;40(9):1032-4; author reply 1035-6.
115. Larré S, Tran N, Fan C, Hamadeh H, Champigneulle J, Azzouzi R, Cussenot O, Mangin P, Olivier JL. PGE2 and LTB4 tissue levels in benign and cancerous prostates. *Prostaglandins Other Lipid Mediat*. 2008 Dec;87(1-4):14-9.
116. Fromont G, Yacoub M, Valeri A, Mangin P, Vallancien G, Cancel-Tassin G, Cussenot O. Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2008 Jun;17(6):1505-9.
117. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet*. 2008 Mar;40(3):310-5.
118. Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, Phillips J, Meuth M, Cussenot O, Hamdy FC. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. *Int J Cancer*. 2008 Feb 15;122(4):952-6.
119. Larre S, Azzouzi AR, Cormier L, Cancel-Tassin G, Drelon I, Baschet F, Villette JM, Cussenot O, Mangin P. How is prostate cancer screening perceived by men 50 to 70 years of age? Analysis based on 1,774 screened individuals. *Prog Urol*. 2007 Sep;17(5):939-42.
120. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. *J Clin Oncol*. 2007 Aug 20;25(24):3596-602.
121. Larré S, Azzouzi AR, Cancel-Tassin G, Cormier L, Villette JM, Hoffmann P, Drelon I, Baschet F, Mangin P, Cussenot O. Impact of obesity on PSA in prostate cancer screening. *Prog Urol*. 2007 Jun;17(4):815-8. French.
122. Azzouzi AR, Stoppa-Lyonnet D, Roupret M, Larre S, Mangin P, Cussenot O. BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families. *Int J Urol*. 2007 May;14(5):445-6.
123. Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Low-activity V89L variant in *SRD5A2* is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. *Eur Urol*. 2007 Oct;52(4):1082-7.
124. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-

- wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet.* 2007 May;39(5):645-9.
125. Azzouzi AR, Catto JW, Rehman I, Larre S, Roupret M, Feeley KM, Cussenot O, Meuth M, Hamdy FC. Clinically localised prostate cancer is microsatellite stable. *BJU Int.* 2007 May;99(5):1031-5.
 126. Azzouzi AR, Larre S, Cormier L, Roupret M, Valeri A, Mangin P, Berthon P, Villette JM, Fiet J, Cussenot O. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. *BJU Int.* 2007 Apr;99(4):762-4.
 127. Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. *Clin Cancer Res.* 2007 Mar 15;13(6):1720-5.
 128. Fromont G, Vallancien G, Validire P, Levillain P, Cussenot O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. *Prostate.* 2007 Feb 15;67(3):268-73.
 129. Rouprêt M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. *Urology.* 2006 May;67(5):1028-32.
 130. Cancel-Tassin G, Cussenot O. Genetic susceptibility to prostate cancer. *BJU Int.* 2005 Dec;96(9):1380-5.
 131. Cancel-Tassin G, Cussenot O. Prostate cancer genetics. *Minerva Urol Nefrol.* 2005 Dec;57(4):289-300.
 132. Fromont G, Valeri A, Cher M, Pontes JE, Vallancien G, Validire P, Latil A, Cussenot O. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. *Prostate.* 2005 Dec 1;65(4):341-6.
 133. Valeri A, Fromont G, Sakr W, Azzouzi R, Dey J, Chantrel-Groussard K, Latil A, Berthon P, Cussenot O, Pontes JE, Cher ML. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. *Urol Oncol.* 2005 Mar-Apr;23(2):87-92.
 134. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. *Int J Cancer.* 2005 Mar 20;114(2):174-81.
 135. Thuret R, Chantrel-Groussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. *Br J Cancer.* 2005 Jan 31;92(2):236-40.
 136. Fournier G, Valeri A, Mangin P, Cussenot O. Prostate cancer. Treatment. *Ann Urol (Paris).* 2004 Oct;38(5):225-58.
 137. Fournier G, Valeri A, Mangin P, Cussenot O. Prostate cancer: Diagnosis and staging. *Ann Urol (Paris).* 2004 Oct;38(5):207-24.
 138. Fournier G, Valeri A, Mangin P, Cussenot O. Prostate cancer. Epidemiology. Risk factors. Pathology. *Ann Urol (Paris).* 2004 Oct;38(5):187-206.
 139. Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. *J Urol.* 2004 Oct;172(4 Pt 1):1382-5.
 140. Algarté-Génin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. *Eur Urol.* 2004 Sep;46(3):285-94; discussion 294-5.
 141. Chêne L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P, Latil A. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. *Int J Cancer.* 2004 Sep 20;111(5):798-804.
 142. Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneulle J, Fromont G, Cussenot O, Hamdy FC. S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. *Br J Cancer.* 2004 Aug 16;91(4):739-44.
 143. Cussenot O, Cancel-Tassin G. Genetic susceptibility to prostate cancer. *Med Sci (Paris).* 2004 May;20(5):562-8.

144. Roumier X, Azzouzi R, Valéri A, Guillemin F, Fournier G, Cussenot O, Mangin P, Cormier L. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer. *Eur Urol.* 2004 Mar;45(3):280-5; author reply 285-6.
145. Fontaine E, Cussenot O. Genetic features of prostatic cancer. *Prog Urol.* 2003 Nov;13(5 Suppl 2):1278.
146. Latil A, Bièche I, Chêne L, Laurendeau I, Berthon P, Cussenot O, Vidaud M. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. *Clin Cancer Res.* 2003 Nov 15;9(15):5477-85.
147. Fromont G, Joulin V, Chantrel-Groussard K, Vallancien G, Guillonneau B, Validire P, Latil A, Cussenot O. Allelic losses in localized prostate cancer: association with prognostic factors. *J Urol.* 2003 Oct;170(4 Pt 1):1394-7.
148. Cancel-Tassin G, Latil A, Rousseau F, Mangin P, Bottius E, Escary JL, Berthon P, Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. *Eur Urol.* 2003 Oct;44(4):487-90.
149. Latil A, Chêne L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. *Prostate.* 2003 Sep 15;57(1):39-50.
150. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. *Urology.* 2003 Jun;61(6):1193-7.
151. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demenais F. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. *Ann Hum Genet.* 2003 Mar;67(Pt 2):125-37.
152. Latil A, Chêne L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O. Quantification of expression of netrins, slits and their receptors in human prostate tumors. *Int J Cancer.* 2003 Jan 20;103(3):306-15.
153. Maier C, Rösch K, Herkommer K, Bochum S, Cancel-Tassin G, Cussenot O, Häussler J, Assum G, Vogel W, Paiss T. A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer. *Eur Urol.* 2002 Sep;42(3):301-7.
154. Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot O, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. *J Urol.* 2002 Aug;168(2):483-7.
155. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. *Prostate.* 2002 Aug 1;52(3):245-52.
156. Cormier L, Guillemin F, Valéri A, Fournier G, Cussenot O, Mangin P, Litwin MS. Impact of prostate cancer screening on health-related quality of life in at-risk families. *Urology.* 2002 Jun;59(6):901-6.
157. Latil A, Morant P, Fournier G, Mangin P, Berthon P, Cussenot O. CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer. *Int J Cancer.* 2002 Jun 10;99(5):689-96.
158. Cormier L, Valéri A, Azzouzi R, Fournier G, Cussenot O, Berthon P, Guillemin F, Mangin P. Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing. *Prostate.* 2002 Jun 1;51(4):276-85.
159. Bièche I, Latil A, Parfait B, Vidaud D, Laurendeau I, Lidereau R, Cussenot O, Vidaud M. CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors. *Eur Urol.* 2002 Mar;41(3):335-41.
160. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochanch-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. *Cancer.* 2001 Sep 1;92(5):1130-7.
161. Cancel-Tassin G, Latil A, Valéri A, Guillaume E, Mangin P, Fournier G, Berthon P, Cussenot O. No evidence of linkage to HPC20 on chromosome 20q13 in hereditary prostate cancer. *Int J Cancer.* 2001 Aug 1;93(3):455-6.
162. Latil A, Guérard M, Berthon P, Cussenot O. 12p12-13 deletion in prostate tumors and quantitative expression of CDKN1B and ETV6 candidate genes. *Genes Chromosomes Cancer.* 2001 Jun;31(2):199-200.

163. Cancel-Tassin G, Latil A, Valéri A, Mangin P, Fournier G, Berthon P, Cussenot O. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. *Eur J Hum Genet.* 2001 Feb;9(2):135-42.
164. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. *Cancer Res.* 2001 Mar 1;61(5):1919-26.
165. Cussenot O, Teillac P, Berthon P, Latil A. Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer. *Eur J Intern Med.* 2001 Feb;12(1):17-19.
166. Cussenot O, Valeri A. Heterogeneity in genetic susceptibility to prostate cancer. *Eur J Intern Med.* 2001 Feb;12(1):11-16.
167. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. *Prostate.* 2001 Jan 1;46(1):2-10.
168. Cussenot O, Fournier G. Genetics and urology. *Prog Urol.* 2000 Nov;10(5):681-1097.
169. Latil A, Vidaud D, Valéri A, Fournier G, Vidaud M, Lidereau R, Cussenot O, Bièche I. htert expression correlates with MYC over-expression in human prostate cancer. *Int J Cancer.* 2000 Mar 20;89(2):172-6.
170. Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. *Int J Cancer.* 2000 Mar 20;89(2):167-71.
171. Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, Berthon P, Cussenot O. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. *Prostate.* 2000 Sep 15;45(1):66-71.
172. Naimi B, Latil A, Berthon P, Cussenot O. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer. *Int J Cancer.* 2000 Aug 1;87(3):455-6.
173. Valeri A, Fournier G, Morin V, Morin JF, Drelon E, Mangin P, Teillac P, Berthon P, Cussenot O. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. *Int J Cancer.* 2000 Jun 15;86(6):883-7. Correa-Cerro L, Berthon P, Häussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. *Hum Genet.* 1999 Sep;105(3):281-7.
174. Valeri A, Drelon E, Paiss T, Vogel W, de Petriconi R, Hautmann R, Fournier G, Mangin P, Berthon P, Cussenot O. Genetic analysis of familial prostatic cancer: localization of a gene predisposing to prostatic cancer (PCaP) on chromosome 1q 42.2-43. *Prog Urol.* 1999 Sep;9(4):680-8.
175. Valeri A, Drelon E, Azzouzi R, Delannoy A, Teillac P, Fournier G, Mangin P, Berthon P, Cussenot O. Epidemiology of familial prostatic cancer: 4-year assessment of French studies. *Prog Urol.* 1999 Sep;9(4):672-9.
176. Latil A, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R. Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer. *Prostate.* 1999 Sep 1;40(4):225-31.
177. Latil A, Bièche I, Pesche S, Volant A, Valéri A, Fournier G, Cussenot O, Lidereau R. Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. *Hum Pathol.* 1999 Jul;30(7):809-15.
178. Ropiquet F, Huguenin S, Villette JM, Ronflé V, Le Brun G, Maitland NJ, Cussenot O, Fiet J, Berthon P. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. *Int J Cancer.* 1999 Jul 19;82(2):237-43.
179. Correa-Cerro L, Wöhr G, Häussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantú JM, Vogel W. (CAG)_nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. *Eur J Hum Genet.* 1999 Apr;7(3):357-62.
180. Le Brun G, Aubin P, Soliman H, Ropiquet F, Villette JM, Berthon P, Créminon C, Cussenot O, Fiet J. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. *Cytokine.* 1999 Feb;11(2):157-62.

181. Latil A, Pesche S, Valeri A, Cussenot O, Fournier G, Lidereau R. Common delta2 and delta8 RB1 variants in human breast and prostate tissues. *Int J Cancer*. 1999 Feb 9;80(4):632-3.
182. Andrawiss M, Opolon P, Benihoud K, Devauchelle P, Di Falco N, Villette JM, Kremer E, Saulnier P, Berthon P, Perricaudet M, Cussenot O. Adenovirus-mediated gene transfer in dog prostate: a preclinical study of a relevant model system for gene therapy of human prostatic cancer. *Prostate Cancer Prostatic Dis*. 1999 Jan;2(1):25-35.
183. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. *Prostate Suppl*. 1998;8:43-51.
184. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. *Oncogene*. 1998 Jun 4;16(22):2879-83.
185. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wöhr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanché H, Bellané-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot O. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. *Am J Hum Genet*. 1998 Jun;62(6):1416-24.
186. Cussenot O, Valeri A, Berthon P, Fournier G, Mangin P. Hereditary prostate cancer and other genetic predispositions to prostate cancer. *Urol Int*. 1998;60 Suppl 2:30-4; discussion 35.
187. Latil A, Bièche I, Fournier G, Cussenot O, Pesche S, Lidereau R. Molecular analysis of the FHIT gene in human prostate cancer. *Oncogene*. 1998 Apr 9;16(14):1863-8.
188. Berthon P, Waller AS, Villette JM, Loridon L, Cussenot O, Maitland NJ. Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. *Int J Cancer*. 1997 Dec 10;73(6):910-6.
189. Ropiquet F, Berthon P, Villette JM, Le Brun G, Maitland NJ, Cussenot O, Fiet J. Constitutive expression of FGF2/bFGF in non-tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype. *Int J Cancer*. 1997 Jul 29;72(3):543-7.
190. Latil A, Cussenot O, Fournier G, Lidereau R. Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours. *Int J Cancer*. 1997 Jun 11;71(6):1118.
191. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. *Cancer Res*. 1997 Mar 15;57(6):1058-62.
192. Cussenot O. Growth factors and prostatic tumors. *Ann Endocrinol (Paris)*. 1997;58(5):370-80.
193. Latil A, Fournier G, Cussenot O, Lidereau R. Differential chromosome allelic imbalance in the progression of human prostate cancer. *J Urol*. 1996 Dec;156(6):2079-83.
194. Cussenot O, Valeri A, Meria P, Berthon P, Fournier G, Teillac P, Mangin, Le Duc A. Genetic aspects in cancers of the prostate. *Pathol Biol (Paris)*. 1996 Oct;44(8):737-43.
195. Latil A, Cussenot O, Fournier G, Lidereau R. The BRCA2 gene is not relevant to sporadic prostate tumours. *Int J Cancer*. 1996 Apr 10;66(2):282-3.
196. Valeri A, Berthon P, Fournier G, Buzzi JC, Briollais L, Meria P, Blanche H, Bellanne-Chantelot C, Teillac P, Demenais F, Mangin P, Cohen N, Le Duc A, Cussenot O. The PROGENE study, the French project of genetic analysis of familial prostatic cancer: recruitment and analysis. *Prog Urol*. 1996 Apr;6(2):226-35. French.
197. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. *Clin Cancer Res*. 1995 Nov;1(11):1385-9.
198. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ. A microdissection approach to detect molecular markers during progression of prostate cancer. *Br J Cancer*. 1995 Oct;72(4):946-51.
199. Latil A, Baron JC, Cussenot O, Fournier G, Boccon-Gibod L, Le Duc A, Lidereau R. Oncogene amplifications in early-stage human prostate carcinomas. *Int J Cancer*. 1994 Dec 1;59(5):637-8.
200. Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Le Duc A, Rouëssé J, Lidereau R. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. *Genes Chromosomes Cancer*. 1994 Oct;11(2):119-25.

Cancer de la Vessie et des Voies Excrétrices Supérieures / Bladder & Upper Urinary Tract Cancer

1. Ismail S, Karsenty G, Chartier-Kastler E, Cussenot O, Compérat E, Rouprêt M, Phé V. Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. *Neurourol Urodyn*. 2017 Nov 23 (Sous presse).
2. Manach Q, Cussenot O, Rouprêt M, Gamé X, Chartier-Kastler E, Reus C, Camparo P, Compérat E, Phé V. Analysis of bladder cancer subtypes in neurogenic bladder tumors. *Can J Urol*. 2018 Feb;25(1):9161-9167.
3. Léon P, Cancel Tassin G, Sighar K, Compérat E, Gaffory C, Ondet V, Hugonin S, Audouin M, Doizi S, Traxer O, Ciofu C, Rouprêt M, Lacave R, Cussenot O. Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, amini-array comparative genomic hybridisation-based test. *Prog Urol*. 2017 Jun -Jul;27(8-9):451-457.
4. Seisen T, Shariat SF, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, Rouprêt M. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract **urothelial** carcinoma. *World J Urol*. 2017 Apr;35(4):535-548.
5. Roperch JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Rouporet M, Phe V, Ciofu C, Tubach F, Cussenot O, Incitti R. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. *BMC Cancer*. 2016 Sep 1;16:704.
6. Seisen T, Nison L, Remzi M, Klatte T, Mathieu R, Lucca I, Bozzini G, Capitanio U, Novara G, Cussenot O, Compérat E, Renard-Penna R, Peyronnet B, Merseburger AS, Fritsche HM, Hora M, Shariat SF, Colin P, Rouprêt M. Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. *J Urol*. 2016 May;195(5):1354-61.
7. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeny LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castela J, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Rouporet M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G Jr, Grubb R 3rd, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF Jr, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Hum Mol Genet*. 2016 Mar 15;25(6):1203-14.
8. Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Rouporet M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O, Grandchamp B. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. *Urology*. 2015 Dec;86(6):1185-90.
9. Haddad M, Cloutier J, Cornu JN, Villa L, Terrasa JB, Benbouzid S, Audouin M, Cussenot O, Traxer O. Immediate Nephroureterectomy or After Attempting Conservative Treatment, on Elective Indications, for Upper Urinary Tract Urothelial Carcinoma: Comparison of the Pathology Reports on a Retrospective Monocentric Study. *J Endourol*. 2015 Aug;29(8):969-73.
10. Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, Compérat E, Mozer P, Cussenot O, Shariat SF, Rouprêt M. A Systematic Review and Meta-analysis of

- Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. *Eur Urol.* 2015 Jun;67(6):1122-1133.
11. Comp rat E, Larr  S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Hou de N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinski SC, Cussenot O, Souli  M, Pfister C. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. *Virchows Arch.* 2015 May;466(5):589-94.
 12. Ph  V, Roupr t M, Cussenot O, Chartier-Kastler E, Gam  X, Comp rat E. Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. *BJU Int.* 2015 Apr;115 Suppl6:28-32.
 13. Seisen T, Cancel-Tassin G, Colin P, Cussenot O, Roupr t M. Carcinogenic pathways and natural history of upper tract urothelial carcinomas:state-of-the-art review for the yearly scientific report of the French National Association of Urology. *Prog Urol.* 2014 Nov;24(15):943-53.
 14. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, Shariat SF, Roupr t M. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int.* 2014 Nov;114(5):733-40.
 15. Fu YP, Kohaar I, Moore LE, Lenz P, Figueroa JD, Tang W, Porter-Gill P, Chatterjee N, Scott-Johnson A, Garcia-Closas M, Muchmore B, Baris D, Paquin A, Ylaya K, Schwenn M, Apolo AB, Karagas MR, Tarway M, Johnson A, Mumy A, Schned A, Guedez L, Jones MA, Kida M, Hosain GM, Malats N, Kogevinas M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Wu X, Purdue M, Andriole GL Jr, Grubb RL3rd, Black A, Landi MT, Caporaso NE, Vineis P, Siddiq A, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Severi G, Weiderpass E, Krogh V, Dorrnsoro M, Travis RC, Tj nneland A, Brennan P, Chang-Claude J, Riboli E, Prescott J, Chen C, De Vivo I, Giovannucci E, Hunter D, Kraft P, Lindstrom S, Gapstur SM, Jacobs EJ, Diver WR, Albanes D, Weinstein SJ, Virtamo J, Kooperberg C, Hohensee C, Rodabough RJ, Cortessis VK, Conti DV, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Haiman CA, Cussenot O, Cancel-Tassin G, Roupret M, Comperat E, Porru S, Carta A, Pavanello S, Arici C, Mastrangelo G, Grossman HB, Wang Z, Deng X, Chung CC, Hutchinson A, Burdette L, Wheeler W, Fraumeni J Jr, Chanock SJ, Hewitt SM, Silverman DT, Rothman N, Prokunina-Olsson L. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. *Cancer Res.* 2014 Oct 15;74(20):5808-18.
 16. Figueroa JD, Han SS, Garcia-Closas M, Baris D, Jacobs EJ, Kogevinas M, Schwenn M, Malats N, Johnson A, Purdue MP, Caporaso N, Landi MT, Prokunina-Olsson L, Wang Z, Hutchinson A, Burdette L, Wheeler W, Vineis P, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorrnsoro M, Travis R, Tj nneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Karagas MR, Schned A, Armenti KR, Hosain GM, Haiman CA, Fraumeni JF Jr, Chanock SJ, Chatterjee N, Rothman N, Silverman DT. Genome-wide interaction study of smoking and bladder cancer risk. *Carcinogenesis.* 2014 Aug;35(8):1737-44.
 17. Munbahuhal G, Drouin SJ, Mozer P, Colin P, Ph  V, Cussenot O, Roupr t M. Malnourishment in bladder cancer and the role of immunonutrition at the time of cystectomy: an overview for urologists. *BJU Int.* 2014 Aug;114(2):177-84.
 18. Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Ph  V, Ouzzane A, Droupy S, Ruffion A, de La Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Roupr t M; French Collaborative National Working-Group on UTUC. Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. *BJU Int.* 2014 Apr;113(4):574-80.
 19. Cussenot O, Sighar K, Mohammed M, Hugonin S, Ondet V, Larre S, Lacave R, Roupret M, Cancel-Tassin G. Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of

- non-muscle-invasive bladder transitional cell carcinoma. *World J Urol.* 2014 Apr;32(2):551-7.
20. Masson-Lecomte A, Colin P, Bozzini G, Nison L, de La Taille A, Comperat E, Zerbib M, Rozet F, Cathelineau X, Valeri A, Ruffion A, Guy L, Droupy S, Cussenot O, Rouprêt M. Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2014 Apr;32(2):531-7.
 21. Colin P, Ghoneim TP, Nison L, Seisen T, Lechevallier E, Cathelineau X, Ouzzane A, Zerbib M, Long JA, Ruffion A, Crouzet S, Cussenot O, Audouin M, Irani J, Gardic S, Gres P, Audenet F, Roumigué M, Valeri A, Rouprêt M. Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. *World J Urol.* 2014 Apr;32(2):507-12.
 22. Bourgade V, Drouin SJ, Yates DR, Parra J, Bitker MO, Cussenot O, Rouprêt M. Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. *World J Urol.* 2014 Apr;32(2):475-9.
 23. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G Jr, Grubb R 3rd, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF Jr, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Hum Mol Genet.* 2014 Mar 1;23(5):1387-98.
 24. Schäfer C, Etori D, Rouprêt M, Phé V, Tualle JM, Tinet E, Avrillier S, Egrot C, Traxer O, Cussenot O. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. *J Urol.* 2013 Jul;190(1):271-7.
 25. Hurel S, Rouprêt M, Ouzzane A, Rozet F, Xylinas E, Zerbib M, Berod AA, Ruffion A, Adam E, Cussenot O, Houlgatte A, Phé V, Nouhaud FX, Bensadoun H, Delage F, Guillotreau J, Guy L, Karsenty G, De La Taille A, Colin P; French Collaborative National Database on UTUC. Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int.* 2013 Jun;111(8):1199-207.
 26. Audenet F, Yates DR, Cussenot O, Rouprêt M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). *Urol Oncol.* 2013 May;31(4):407-13.
 27. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF; French National Database on Upper Tract Tumors; Upper Tract Urothelial Carcinoma Collaboration. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. *J Urol.* 2013 May;189(5):1662-9.
 28. Compérat E, Jacquet SF, Varinot J, Conort P, Roupret M, Chartier-Kastler E, Bitker MO, Witjes JA, Cussenot O. Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. *Virchows Arch.* 2013 Mar;462(3):343-8.
 29. Ouzzane A, Colin P, Ghoneim TP, Zerbib M, De La Taille A, Audenet F, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Maurin C, Nouhaud FX, Phé V, Polguer T, Roumigué M, Ruffion A, Rouprêt M. The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. *World J Urol.* 2013 Feb;31(1):189-97.

30. Drouin SJ, Yates DR, Hupertan V, Cussenot O, Rouprêt M. A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. *World J Urol.* 2013 Feb;31(1):109-16.
31. Nison L, Rouprêt M, Bozzini G, Ouzzane A, Audenet F, Pignot G, Ruffion A, Cornu JN, Hurel S, Valeri A, Roumiguie M, Polguer T, Hoarau N, Mérigot de Treigny O, Xylinas E, Matte A, Droupy S, Fais PO, Descazeaud A, Colin P; MD for the French Collaborative National Database on UUT-UC. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. *World J Urol.* 2013 Feb;31(1):69-76.
32. Xylinas E, Colin P, Audenet F, Phe V, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyère F, Polguer T, Ruffion A, Valeri A, Rozet F, Long JA, Zerbib M, Rouprêt M. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. *World J Urol.* 2013 Feb;31(1):61-8.
33. Yates DR, Rouprêt M, Drouin SJ, Audouin M, Cancel-Tassin G, Comperat E, Bitker MO, Cussenot O. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. *World J Urol.* 2013 Feb;31(1):53-9.
34. Audenet F, Colin P, Yates DR, Ouzzane A, Pignot G, Long JA, Soulie M, Phé V, Bensadoun H, Guy L, Ruffion A, Valeri A, Cormier L, Droupy S, de La Taille A, Saint F, Fais PO, Houlgatte A, Cussenot O, Rouprêt M; French Collaborative National Database on UUT-UC. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. *BJU Int.* 2012 Dec;110(11 Pt B):E583-9.
35. Colin P, Ouzzane A, Pignot G, Ravier E, Crouzet S, Ariane MM, Audouin M, Neuzillet Y, Albouy B, Hurel S, Saint F, Guillotreau J, Guy L, Bigot P, De La Taille A, Arroua F, Marchand C, Matte A, Fais PO, Rouprêt M; French Collaborative National Database on U.U.T.-U.C. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. *BJU Int.* 2012 Oct;110(8):1134-41.
36. Scarpini S, Rouprêt M, Renard-Penna R, Camparo P, Cussenot O, Compérat E. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. *Urol Oncol.* 2012 Mar-Apr;30(2):182-7.
37. Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA, Pignot G, Crouzet S, Rozet F, Neuzillet Y, Soulie M, Bodin T, Valeri A, Cussenot O, Rouprêt M; French collaborative national database on UUT-UC. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. *Br J Cancer.* 2012 Mar 13;106(6):1083-8.
38. Audenet F, Traxer O, Yates DR, Cussenot O, Rouprêt M. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. *BJU Int.* 2012 Feb;109(4):608-13; discussion 613-4.
39. Rouprêt M, Drouin SJ, Cancel-Tassin G, Comperat E, Larré S, Cussenot O. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. *J Urol.* 2012 Feb;187(2):424-8.
40. Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyère F, Maurin C, Nouhaud FX, Phe V, Polguer T, Roumiguie M, Ruffion A, Rouprêt M; French Collaborative National Database on UUT-UC. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. *Eur Urol.* 2011 Dec;60(6):1258-65.
41. Phé V, Cussenot O, Bitker MO, Rouprêt M. Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? *BJU Int.* 2011 Jul;108(1):130-8.

42. Cornu JN, Merlet B, Cussenot O, Cancel-Tassin G, Ciofu C, Amarenco G, Haab F. Genetic susceptibility to urinary incontinence: implication of polymorphisms of androgen and oestrogen pathways. *World J Urol.* 2011 Apr;29(2):239-42.
43. Azémar MD, Comperat E, Richard F, Cussenot O, Rouprêt M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. *Urol Oncol.* 2011 Mar-Apr;29(2):130-6.
44. Larré S, Camparo P, Comperat E, Gil Diez De Medina S, Traxer O, Roupret M, Sebe P, Cancel-Tassin G, Sighar K, Lozach F, Cussenot O. Diagnostic, staging, and grading of urothelial carcinomas from urine: performance of BCA-1, a mini-array comparative genomic hybridisation-based test. *Eur Urol.* 2011 Feb;59(2):250-7.
45. Compérat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I, Cussenot O, Samaratunga H. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. *Pathology.* 2010 Dec;42(7):650-4.
46. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeny LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurdau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nat Genet.* 2010 Nov;42(11):978-84.
47. Ouzaid I, Cussenot O, Rouprêt M. Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. *Urology.* 2010 Aug;76(2):260-3.
48. Cornu JN, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. *World J Urol.* 2010 Apr;28(2):151-6.
49. Varinot J, Camparo P, Roupret M, Bitker MO, Capron F, Cussenot O, Witjes JA, Compérat E. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. *Virchows Arch.* 2009 Nov;455(5):449-53.
50. Azémar MD, Audouin M, Revaux A, Misraï V, Comperat E, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Rouprêt M. Primary upper urinary tract tumors and subsequent location in the bladder. *Prog Urol.* 2009 Oct;19(9):583-8.
51. Phé V, Cussenot O, Rouprêt M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. *BJU Int.* 2009 Oct;104(7):896-901.
52. Compérat E, Roupret M, Conort P, Chartier-Kastler E, Bitker MO, Richard F, Capron F, Haertig A, Cussenot O, Camparo P. Aurora-A/STK-15 is differentially expressed in the micropapillary variant of bladder cancer. *Urol Int.* 2009;82(3):312-7.
53. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. *Eur Urol.* 2009 Mar;55(3):650-7.
54. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. *Eur Urol.* 2008 Dec;54(6):1226-36.
55. Compérat E, Bièche I, Dargère D, Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron F, Verret C, Cussenot O, Bedossa P, Paradis V. Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. *Urology.* 2008 Oct;72(4):873-7.
56. Eltz S, Comperat E, Cussenot O, Rouprêt M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. *BJU Int.* 2008 Aug 5;102(5):532-5.

57. Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B, Richard F, Hamdy FC, Cussenot O. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int.* 2008 Jun;101(11):1448-53.
58. Compérat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, Capron F, Cussenot O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. *J Urol.* 2008 Mar;179(3):868-72; discussion 872.
59. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC. Behavior of urothelial carcinoma with respect to anatomical location. *J Urol.* 2007 May;177(5):1715-20.
60. Nicolle G, Comperat E, Nicolaïew N, Cancel-Tassin G, Cussenot O. Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. *Ann Oncol.* 2007 Mar;18(3):605-7.
61. Rouprêt M, Traxer O, Tligui M, Conort P, Chartier-Kastler E, Richard F, Cussenot O. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. *Eur Urol.* 2007 Mar;51(3):709-13; discussion 714.
62. Roupret M, Cussenot O, Chartier-Kastler E, Thibault P, Richard F, Conort P, Traxer O. Role of endoscopy in the management of upper urinary tract tumors. *Prog Urol.* 2006 Nov;16(5):537-41. Erratum in: *Prog Urol.* 2007 Apr;17(2):263.
63. Rouprêt M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. *Urology.* 2006 Jun;67(6):1181-7.
64. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. *J Clin Oncol.* 2005 May 1;23(13):2903-10.
65. Rouprêt M, Cussenot O. Transitional cell carcinoma of the upper urinary tract new concepts in management. *Presse Med.* 2005 Apr 23;34(8):601-7.
66. Dumey N, Mongiat-Artus P, Devauchelle P, Lesourd A, Cotard JP, Le Duc A, Marty M, Cussenot O, Cohen-Haguenaer O. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. *Eur Urol.* 2005 Feb;47(2):257-63.
67. Amira N, Cancel-Tassin G, Bernardini S, Cochand-Priollet B, Bittard H, Mangin P, Fournier G, Latil A, Cussenot O. Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: identification of 5 candidates tumor suppressor genes. *Int J Cancer.* 2004 Sep 10;111(4):539-42.
68. Cussenot O, Davin JL. Genetic features of urothelial carcinoma of the bladder and the upper urinary tract. *Prog Urol.* 2003 Nov;13(5 Suppl 2):1233.
69. Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. *Oncogene.* 2003 Nov 27;22(54):8699-706.
70. Amira N, Rivet J, Soliman H, Cancel-Tassin G, Le Duc A, Janin A, Cussenot O. Microsatellite instability in urothelial carcinoma of the upper urinary tract. *J Urol.* 2003 Oct;170(4 Pt 1):1151-4.
71. Amira N, Mourah S, Rozet F, Teillac P, Fiet J, Aubin P, Cortesse A, Desgrandchamps F, Le Duc A, Cussenot O, Soliman H. Non-invasive molecular detection of bladder cancer recurrence. *Int J Cancer.* 2002 Sep 20;101(3):293-7.
72. Naimi B, Latil A, Berthon P, Cussenot O. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer. *Int J Cancer.* 2000 Aug 1;87(3):455-6.
73. Lancelin F, Anidjar M, Villette JM, Soliman A, Teillac P, Le Duc A, Fiet J, Cussenot O. Telomerase activity as a potential marker in preneoplastic bladder lesions. *BJU Int.* 2000 Mar;85(4):526-31.
74. Mourah S, Cussenot O, Vimont V, Desgrandchamps F, Teillac P, Cochand-Priollet B, Le Duc A, Fiet J, Soliman H. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. *Int J Cancer.* 1998 Dec 18;79(6):629-33.

75. Fournier G, Valéri A, Cussenot O. Familial forms of cancer of the urogenital tract: clinical and genetic features. *Prog Urol.* 1996 Jun;6(3):343-55.

Cancer du Rein / Kidney Cancer

1. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage SA, Gaborieau V, McKay JD, Ye Y, Henrion M, Bruinsma F, Jordan S, Severi G, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TE, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Gaziano JM, Sesso HS, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Colli LM, Sampson JN, Besse C, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Mijuskovic M, Ognjanovic M, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Bueno-de-Mesquita HB, Canzian F, Duell EJ, Ljungberg B, Sitaram RT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Larkin J, Choueiri TK, Lathrop GM, Teh BT, Deleuze JF, Wu X, Houlston RS, Brennan P, Chanock SJ, Scelo G, Purdue MP. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. *Eur Urol.* 2017 Nov;72(5):747-754.
2. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. *Nat Commun.* 2017 Jun 9;8:15724.
3. Scelo G, Hofmann JN, Banks RE, Bigot P, Bhatt RS, Cancel-Tassin G, Chew SK, Creighton CJ, Cussenot O, Davis IJ, Escudier B, Frayling TM, Häggström C, Hildebrandt MA, Holcatova I, Johansson M, Linehan WM, McDermott DF, Nathanson KL, Ogawa S, Perlman EJ, Purdue MP, Stattin P, Swanton C, Vasudev NS, Wu X, Znaor A, Brennan P, Chanock SJ. International cancer seminars: a focus on kidney cancer. *Ann Oncol.* 2016 Aug;27(8):1382-5.
4. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. *Mol Oncol.* 2015 Jan;9(1):32-43.
5. Audenet F, Audouin M, Drouin SJ, Comperat E, Mozer P, Chartier-Kastler E, Méjean A, Cussenot O, Shariat SF, Rouprêt M. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. *World J Urol.* 2014 Apr;32(2):513-8.
6. Audenet F, Cancel-Tassin G, Bigot P, Audouin M, Gaffory C, Ondet V, Thibault F, Auribault K, Gazut S, Benhabiles N, Azzouzi AR, Méjean A, Rouprêt M, Cussenot O. Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma. *J Urol.* 2014 Feb;191(2):487-92.
7. Audenet F, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. *BJU Int.* 2012 Jun;109(12):1864-70.

8. Phé V, Yates DR, Renard-Penna R, Cussenot O, Rouprêt M. Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses? *BJU Int.* 2012 Mar;109(6):867-72.
9. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorransoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF Jr, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. *Hum Mol Genet.* 2012 Jan 15;21(2):456-62.
10. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemenev LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorransoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njølstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF Jr, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat Genet.* 2011 Jan;43(1):60-5.
11. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. *PLoS One.* 2010 May 19;5(5):e10715.
12. Thibault F, Cancel-Tassin G, Cussenot O. Low penetrance genetic susceptibility to kidney cancer. *BJU Int.* 2006 Oct;98(4):735-8.
13. Valeri A, Cussenot O. Hereditary forms of kidney cancer and genetic screening. *Prog Urol.* 2003 Nov;13(5 Suppl 2):1201-4.
14. Cussenot O, Fournier G. Genetics and urology. *Prog Urol.* 2000 Nov;10(5):681-1097.